A Phase 4 interventional study of Remimazolam and Normal Saline in Pediatric, Neurosurgery and Sevoflurane Anesthesia, sponsored by Peking University First Hospital. Recruiting at 2 sites in China. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Peking University First Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing remimazolam in Emergence Delirium — 9 open to participants now, 9 under way, none of them phase 3. remimazolam · Emergence Delirium.
Among the 13 studies testing remimazolam in Emergence Delirium, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 6th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →9 of the 13 studies testing remimazolam in Emergence Delirium are open now, in 3 countries. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 65–90 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 65–100
University Hospital of Split · Sites in Croatia
Ages 18–65
Peking University First Hospital · Sites in China
Ages 50–90
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
remimazolam: first FDA approval 2020 (BYFAVO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 1 Year to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 248 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 138 across the 13 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.
11 studies in Emergence Delirium by Peking University First Hospital: 5 open now, 5 under way, none of them phase 3. Of 5 finished, 0 (0%) have results posted.
Among the 11 studies in Emergence Delirium by Peking University First Hospital, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 4, and was the 9th registered.
Peking University First Hospital’s Emergence Delirium studies by the year they started, since 2011.
4 of the studies testing remimazolam in Emergence Delirium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07351474The First Affiliated Hospital with Nanjing Medical UniversityRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | 2026-12-25 |
| NCT07046364Peking University First HospitalRemimazolam and Emergence Delirium in Pediatrics | 2027-01-01 |
| NCT07740655Jeju National University School of MedicineLow-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal Surgery | 2027-07-31 |
| NCT07816068Seoul National University HospitalEffects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies testing remimazolam in Emergence Delirium, from their registry updates:
Among Peking University First Hospital’s 11 in Emergence Delirium:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A loading dose of remimazolam 0.3 mg/Kg was given at anesthesia induction and followed with 1 mg/Kg/h until 10 minutes before the end of surgery. Sevoflurane was used to maintain BIS between 40-60.
Drug: Remimazolam
An identical volume of normal saline was given as placebo. Patients received sevoflurane to maintain anesthesia depth (BIS) 40-60
Drug: Normal Saline
After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.
After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.
Emergence delirium
The Cornell Assessment of Pediatric Delirium (CAPD) was used to assess delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.
Time frame: The subjects were evaluated at 10 minutes, 20 minutes, 30 minutes after admission to PACU or before discharge
Postoperative delirium
The Cornell Assessment of Pediatric Delirium (CAPD) scale was used to assess whether the subjects developed delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.
Time frame: Delirium was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery
Pain score
The FLACC behavioral rating scale was used to evaluate the pain intensity. It mainly includes five indicators: Facial Expression, Legs, Activity, Cry, and Consolability. The score is the sum of the above five indicators, ranging from a minimum of 0 to a maximum of 10. A higher score indicates more obvious discomfort and pain.
Time frame: Pain intensity was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery
Sleep quality within 3 days after surgery
The Numeric Rating Scale (NRS) was used for sleep quality assessment of children by their parents/caregivers within 3 days after surgery. The scores of NRS ranging from a minimum of 0 to a maximum of 10. A lower score indicates poorer sleep quality.
Time frame: Within 3 days after surgery
Sleep quality 7 days after surgery and 1 month after surgery
The Tayside Children's Sleep Questionnaire (TCSQ) was adopted to assess the sleep quality 7 days after surgery and 1 month after surgery.The TCSQ consists of 10 questions, with scores ranging from a minimum of 0 to a maximum of 40. A higher score indicates poorer sleep quality.
Time frame: 7 days after surgery and 1 month after surgery
Postoperative adverse behavior change
Post-hospitalization behavior questionnaire (PHBQ) was used to evaluate the postoperative adverse behavior change. It consists of 26 items, with scores ranging from a minimum of -52 to a maximum of 52. A higher score indicates poorer sleep quality.
Time frame: 1st, 3rd days after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.
Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 24 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remimazolam
Peking University First Hospital →